Cartesian Therapeutics, Inc. RNAC
Regular-session close
After hours · Nov 20, 6:15 PM ET
- YTD
- -14.84%
- 1 year
- -14.13%
5D -0.19 (-3.00%)
- Market cap
- 187.29M
- Revenue (ttm)
- 47.94M
- EPS (ttm)
- -4.78
- Shares out
- 25.41M
- Forward P/E
- -5.54
- YTD return
- -14.84%
- 1-year return
- -14.13%
- 50-day average
- 20.18
- Volume
- 279.91K
- Avg volume
- 137.85K
- Open
- 5.89
- Previous close
- 5.89
- Day's range
- 5.89 – 6.32
- 52-week range
- 5.84 – 10.59
- Analysts
- Buy
- Price target
- 38.17 (+521.6%)
Key statistics
- 200-day average
- 19.88
- Enterprise value
- 278.84M
- Price / sales
- 10.26
- Price / book
- 624.19
- Revenue growth
- -94.10%
- Free cash flow
- -2.93M
- Total cash
- 219.20M
- Total debt
- 14.65M
- Return on equity
- -7029.26%
- Short % of float
- 11.47%
Fundamental scorecard
2 of 25 checks passed on RNAC’s reported financials
2of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.78 | -0.69 | +0.09 | +11.54% |
| Aug 8, 2024 | Jun 1, 2024 | -0.81 | 0.54 | +1.35 | +166.67% |
| May 8, 2024 | Mar 1, 2024 | -0.81 | -1.97 | -1.16 | -143.21% |
| Mar 7, 2024 | Dec 1, 2023 | -0.30 | -2.40 | -2.10 | -700.00% |
| Nov 13, 2023 | Sep 1, 2023 | -2.10 | -2.40 | -0.30 | -14.29% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | BTIG | init | — | Buy |
| Dec 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 3, 2024 | Needham | reit | Buy | Buy |
| Nov 25, 2024 | Needham | reit | Buy | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 8, 2024 | Needham | reit | Buy | Buy |
About Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cartesiantherapeutics.com
News
Your note
Sign in to keep a note on RNAC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARABE TIMOTHY CRAIG | Director | Purchase | Aug 11, 2024 | 21,766 |
| HOGE ELIZABETH | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 10, 2024 | 0 |
| JEWELL CHRISTOPHER M | Officer | Conversion of Exercise of derivative security | Nov 19, 2024 | 39,940 |
| KALAYOGLU MURAT | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 10, 2024 | 0 |
| KURTOGLU METIN | Chief Technology Officer | Conversion of Exercise of derivative security | Dec 9, 2024 | 51,033 |
| MALIK KEMAL | Director | Stock Award(Grant) | Jun 30, 2024 | 5,933 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 11.22% | 2,851,830 | 55.18M | Sep 29, 2024 |
| MPM BioImpact Capital LLC | 2.48% | 629,423 | 12.18M | Sep 29, 2024 |
| Siren, L.L.C. | 2.25% | 572,236 | 11.07M | Sep 29, 2024 |
| Blackrock Inc. | 1.67% | 423,466 | 8.19M | Sep 29, 2024 |
| Citadel Advisors Llc | 1.48% | 375,767 | 7.27M | Sep 29, 2024 |
| JP Morgan Chase & Company | 1.22% | 309,018 | 5.98M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios - Biotechnology | 3.69% | 936,691 | 18.12M | Oct 30, 2024 |
| Fidelity Select Portfolios - Health Care | 1.45% | 368,992 | 7.14M | Oct 30, 2024 |
| Fidelity Growth Company Fund | 1.34% | 341,346 | 6.61M | Oct 30, 2024 |
| Fidelity Advisor Health Care Fund | 0.91% | 230,254 | 4.46M | Oct 30, 2024 |
| iShares Russell 2000 ETF | 0.70% | 177,734 | 3.44M | Oct 30, 2024 |
| Fidelity Advisor Biotechnology Fund | 0.66% | 167,950 | 3.25M | Oct 30, 2024 |
